Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shanghai Key Laboratory, Traditional Chinese Clinical Medicine, Shanghai, China.
Mol Nutr Food Res. 2018 Jan;62(1). doi: 10.1002/mnfr.201700483. Epub 2017 Oct 12.
Nonalcoholic fatty liver disease (NAFLD) is a major health issue throughout the world. However, no validated treatments for NAFLD are currently available. In-depth studies have demonstrated the efficacy of (-)-epigallocatechin-3-gallate (EGCG), a main bioactive chemical extracted from green tea, in treating NAFLD. EGCG exhibits multi-pronged preventive and therapeutic activities, including promoting lipid and glucose metabolism, anti-lipid peroxidation and anti-inflammation activities, anti-fibrosis, and anti-NAFLD related tumor, thus contributing to the mitigation of NAFLD occurrence and progression. The objectives of this paper are to review and discuss the currently known targets, signaling pathways and roles of EGCG that interfere with NAFLD pathogenesis, then providing additional experimental evidence and the foundation for the further studies and clinical applications of EGCG in the prevention and treatment of NAFLD.
非酒精性脂肪性肝病（NAFLD）是全球范围内的一个主要健康问题。然而，目前尚无针对 NAFLD 的经过验证的治疗方法。深入的研究已经证明了从绿茶中提取的主要生物活性化学物质 (-)-表没食子儿茶素-3-没食子酸酯（EGCG）在治疗 NAFLD 方面的功效。EGCG 具有多方面的预防和治疗作用，包括促进脂质和葡萄糖代谢、抗脂质过氧化和抗炎活性、抗纤维化以及抗与 NAFLD 相关的肿瘤，从而有助于减轻 NAFLD 的发生和进展。本文的目的是综述和讨论目前已知的 EGCG 靶点、信号通路和作用，这些靶点、信号通路和作用干扰了 NAFLD 的发病机制，为进一步研究和临床应用 EGCG 预防和治疗 NAFLD 提供了额外的实验证据和基础。
Zotero 插件